Healthcare > Pharmaceuticals & Biotechnology
•770 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (770)
%
| Company | Market Cap | Price |
|---|---|---|
|
Lilly is a large-cap pharmaceutical company with a globally diversified product portfolio and substantial revenue.
|
$789.93B |
$833.49
-2.86%
|
|
Company's oncology-focused biotech portfolio and cancer therapies (e.g., CAR-VYKTI, bispecifics) represent a major product category.
|
$458.89B |
$190.72
-0.67%
|
|
Skyrizi and Rinvoq are monoclonal antibody therapeutics, directly manufactured and sold by AbbVie in immunology.
|
$431.71B |
$236.56
-1.80%
|
|
AstraZeneca highlights its Antibody Drug Conjugate (ADC) platform with multiple ADC programs (e.g., Enhertu) and P-Sam in development.
|
$262.04B |
$84.53
-1.28%
|
|
Novo Nordisk is a Large Cap Pharma company that directly develops and sells GLP-1 diabetes/obesity therapies (e.g., Ozempic, Wegovy).
|
$256.75B |
$56.93
-2.84%
|
|
Novartis' oncology portfolio (Kisqali, Scemblix, Pluvicto) is a core revenue driver and growth engine.
|
$252.00B |
$130.00
|
|
Abbott is a large-cap pharmaceutical player with an established pharma portfolio and pipeline.
|
$230.52B |
$132.57
-1.21%
|
|
Keytruda is a monoclonal antibody cancer therapy and a core revenue driver in Merck's oncology franchise.
|
$200.78B |
$79.96
-0.16%
|
|
Oncomine Dx Target Test and Oncomine Dx Express Test are companion diagnostics enabling rapid genomic profiling.
|
$198.11B |
$524.80
-1.88%
|
|
Amgen has a leading biosimilars franchise with PAVBLU, WEZLANA, BEKEMV and ongoing biosimilar launches.
|
$156.00B |
$290.13
-2.04%
|
|
Gilead has a deep oncology franchise through Trodelvy and a broader strategy into cancer therapies.
|
$145.76B |
$117.18
-0.40%
|
|
Companion Diagnostics captures biomarker-based diagnostic tests used to identify patients for targeted therapies.
|
$144.89B |
$202.46
-1.20%
|
|
Intera Oncology hepatic artery infusion pump aligns with oncology device/therapy solutions.
|
$141.15B |
$95.41
-1.94%
|
|
Pfizer is a large-cap pharma company with a diversified global product portfolio.
|
$137.19B |
$24.09
-0.15%
|
|
Dupixent and Beyfortus are monoclonal antibody therapeutics, a core Sanofi product class.
|
$120.19B |
$98.46
|
|
Vertex's ALYFTREK (CFTR modulator) and TRIKAFTA are oral small-molecule therapeutics for cystic fibrosis, representing a core product category.
|
$104.72B |
$407.79
-1.34%
|
|
Direct sale and distribution of generic drugs, a major CVS drug category.
|
$98.55B |
$77.90
-0.33%
|
|
Opdivo and the oncology Growth Portfolio are core to Bristol-Myers Squibb's business.
|
$89.46B |
$43.96
-1.83%
|
|
GSK's portfolio includes multiple vaccines (Arexvy, Shingrix, Penmenvy), making Vaccines a core product area.
|
$88.43B |
$21.73
|
|
Zoetis develops and commercializes vaccines for animals.
|
$62.82B |
$141.11
-1.59%
|
|
Regeneron’s Dupixent and Libtayo represent core monoclonal antibody therapeutics driving a large portion of revenue.
|
$60.96B |
$564.63
-0.82%
|
|
Alnylam's core offerings are RNA interference therapeutics (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO), defining the primary product category as RNAi Therapeutics.
|
$60.04B |
$460.46
+0.04%
|
|
Core focus on immunology therapeutics and autoimmune disease treatments (VYVGART and pipeline).
|
$47.65B |
$796.92
-0.76%
|
|
Takeda's dengue vaccine QDENGA demonstrates a clear vaccines product line with strong global demand.
|
$43.58B |
$27.33
-2.62%
|
|
Takeda is a Large Cap Pharmaceutical company with a diversified global pharma portfolio.
|
$43.47B |
$13.71
-1.01%
|
|
Offers over-the-counter pain relief/analgesics under its brands.
|
$41.10B |
$9.00
-0.22%
|
|
BIOVECTRA and NASD CDMO capabilities position Agilent as a contract manufacturing organization.
|
$40.00B |
$140.11
-0.12%
|
|
Cardinal Health operates BioPharma Solutions, a contract manufacturing organization that provides outsourced pharmaceutical manufacturing services.
|
$37.44B |
$156.88
-0.61%
|
|
Alcon markets Tryptyr (AR-15512), a prescription eye drop, representing a direct ophthalmic drug product.
|
$35.64B |
$72.05
-3.44%
|
|
BeOne Medicines is an oncology-focused biotech company delivering cancer therapies, including BRUKINSA and TEVIMBRA.
|
$34.59B |
$320.10
-3.00%
|
|
IQVIA operates as a Contract Research Organization delivering outsourced R&D services across clinical research and real-world evidence.
|
$34.28B |
$198.17
-2.56%
|
|
Radiopharmaceuticals (Flyrcado, Vizamyl) form a major diagnostic product category.
|
$32.51B |
$71.01
-4.05%
|
|
Tylenol and other OTC analgesics are core self-care offerings that Kenvue directly manufactures and sells.
|
$31.52B |
$16.18
-1.49%
|
|
Insmed operates as a large-cap pharmaceutical company with a multi-asset pipeline and ARIKAYCE as a key revenue driver.
|
$29.57B |
$162.33
-1.08%
|
|
BioNTech directly develops and commercializes vaccines, including its COVID-19 vaccine franchise and ongoing vaccine-related therapies.
|
$24.47B |
$102.06
-2.54%
|
|
Labcorp operates as an outsourced drug development and central-laboratory service provider, i.e., a Contract Research Organization (CRO) in biopharma.
|
$23.26B |
$277.88
-0.11%
|
|
Teva is a leading generic drug manufacturer with a broad portfolio and ongoing growth in generic sales.
|
$22.95B |
$20.01
+0.05%
|
|
Signatera functions as a companion diagnostic to guide cancer therapy decisions.
|
$22.07B |
$161.61
+0.94%
|
|
Direct product: LEQEMBI is Biogen's monoclonal antibody therapy for Alzheimer's disease.
|
$21.48B |
$146.57
-2.29%
|
|
Genmab operates as a biotechnology company focused on oncology with proprietary antibody platforms and therapies.
|
$21.05B |
$31.81
-0.28%
|
|
Contract Manufacturing Organizations captures the CDMO-like manufacturing services via the Pharmaceutics International acquisition.
|
$20.82B |
$193.99
-5.75%
|
|
Acquisition of Atomic Alchemy to produce radioisotopes and VIPR medical/industrial isotopes.
|
$20.49B |
$147.16
+6.88%
|
|
UTHR's core PAH/PH-ILD prostacyclin therapies drive the revenue base, including Tyvaso DPI, Nebulized Tyvaso, Remodulin/Remunity, and Orenitram.
|
$19.85B |
$440.00
-1.27%
|
|
Genmab is a oncology-focused biotechnology company, generating revenue from cancer therapeutics (EPKINLY, Tivdak) and a pipeline centered on anticancer biologics.
|
$19.49B |
$315.00
|
|
Contract-Manufactured Products segment indicates CDMO-style design, manufacture, and assembly of complex devices.
|
$18.81B |
$261.77
-1.19%
|
|
BWXT's Medical segment produces radiopharmaceuticals and nuclear medicine isotopes used in diagnostics and therapy.
|
$17.37B |
$190.08
-2.82%
|
|
Hereditary cancer screening and biomarker-driven diagnostics align with Companion Diagnostics.
|
$16.69B |
$96.39
-4.47%
|
|
Incyte's core business includes small-molecule therapeutics (e.g., oral JAK inhibitors) and an actively developed pipeline of other oral NCEs.
|
$16.22B |
$83.80
-1.42%
|
|
Summit's direct product focus is ivonescimab in oncology, licensed for development and commercialization, making Biotech - Oncology a core segment.
|
$15.86B |
$21.35
-6.28%
|
|
ICON is a Contract Research Organization (CRO) providing outsourced drug development services across all clinical trial phases and expanded scale via the PRA acquisition.
|
$15.15B |
$183.49
-2.46%
|
|
INGREZZA and the Neurocrine CNS portfolio are driven by oral small-molecule therapeutics, including a broad pipeline of additional small-molecule CNS agents.
|
$14.51B |
$146.95
+0.38%
|
|
Medpace is a full-service Contract Research Organization (CRO) delivering outsourced clinical development and regulatory services for Phase I–IV trials.
|
$14.41B |
$501.22
-3.28%
|
|
Peptide manufacturing capability aligns with contract manufacturing of biologics/pharma, expanding vertical integration.
|
$12.08B |
$53.95
-7.45%
|
|
Ascendis is cornerstone in rare-disease therapies with marketed products YORVIPATH and SKYTROFA and a pipeline (TransCon CNP) targeting rare conditions, matching the Biotech - Rare Diseases theme.
|
$12.06B |
$209.55
-2.16%
|
|
Dr. Reddy's is a leading producer of generic drugs with a broad, global portfolio.
|
$11.96B |
$14.34
+1.63%
|
|
Viatris is a leading manufacturer of generic drugs with a diversified portfolio of off-patent medicines.
|
$11.17B |
$9.52
-0.42%
|
|
Ionis has multiple late-stage and marketed assets across rare diseases (e.g., FCS, HAE, Alexander disease, Angelman), forming a core rare-disease portfolio.
|
$11.14B |
$69.97
-0.04%
|
|
The company operates within oncology diagnostics and biotech-driven test development, aligning with Biotech - Oncology.
|
$11.01B |
$58.34
-2.11%
|
|
Roivant's immunology portfolio (FcRn inhibitors IMVT-1402 and batoclimab) targets autoimmune/inflammatory diseases, aligning with Immunology Therapeutics.
|
$10.90B |
$16.04
-0.50%
|
|
BBP-812 is an AAV9 gene therapy for Canavan disease, directly produced by BridgeBio.
|
$10.54B |
$55.49
+1.20%
|
|
QIAstat-Dx is a platform used in companion diagnostics.
|
$10.49B |
$46.85
-1.10%
|
|
Exelixis develops oncology-focused biotech therapies, including small-molecule TKIs and antibody-based modalities within cancer.
|
$10.40B |
$38.15
-1.34%
|
|
Moderna directly develops and sells vaccines using its mRNA platform (e.g., Spikevax and pipeline vaccines like mRESVIA and mRNA-1283), which are core products highlighted in the article.
|
$10.38B |
$26.83
-3.42%
|
|
Walgreens sells OTC pain relief and analgesics as a major consumer health product category.
|
$10.36B |
$11.98
|
|
BioMarin focuses on rare genetic disorders and enzyme therapies, aligning with the rare-disease biotech investment theme.
|
$10.03B |
$52.32
-3.40%
|
|
OTC pain relief products are a product category Albertsons offers in-store.
|
$9.86B |
$17.12
-1.10%
|
|
Vaccines are a key product line in Elanco's portfolio (pet and farm vaccines mentioned).
|
$9.74B |
$19.61
+3.59%
|
|
Rezdiffra is an oral, liver-directed small-molecule therapeutic, which is Madrigal's core product.
|
$9.54B |
$429.60
+0.21%
|
|
DCI's Life Sciences activities include manufacturing-grade IsoTag AAV reagent for GMP bioprocessing, a concrete product line.
|
$9.31B |
$79.88
-2.06%
|
|
Verona Pharma operates as a pharmaceutical company with a commercial COPD therapy, aligning with the Large Cap Pharma category.
|
$9.10B |
$106.91
|
|
Biotech - Gene Therapy reflects Bio-Techne's involvement in cell and gene therapy platforms and enabling technologies.
|
$8.72B |
$55.63
+6.51%
|
|
Aptar's core offering is drug delivery platforms, including nose-to-brain and inhaled delivery systems (e.g., Precision Nasal 3, Quotri DPIs).
|
$8.65B |
$130.93
-0.01%
|
|
Regencell's core focus is the development of neuropsychiatric therapeutics (ADHD/ASD) using proprietary formulations, clearly fitting neuropsychiatric drug development.
|
$8.31B |
$16.81
-8.54%
|
|
AYVAKIT and the pipeline assets are oral small-molecule therapeutics targeting KIT, making 'Oral Small Molecule Therapeutics' a core product category.
|
$8.27B |
$129.46
|
|
Sabre Bio adds an antibody discovery platform that Bio-Rad now offers, aligning with its portfolio.
|
$8.10B |
$284.88
|
|
Jazz is a large-cap pharma company with a diversified revenue base and pipeline.
|
$7.99B |
$129.59
-0.16%
|
|
Revolution Medicines focuses on oncology with a pipeline of RAS(ON) inhibitors and has clinically advanced small-molecule cancer therapies (e.g., daraxonrasib, elironrasib, zoldonrasib).
|
$7.92B |
$42.51
-1.41%
|
|
Halozyme's ENHANZE subcutaneous drug-delivery platform enables oncology therapeutics with rapid, high-volume subcutaneous administration and royalties from major cancer products.
|
$7.90B |
$64.10
-2.20%
|
|
Corcept's portfolio centers on oral small-molecule therapies (Korlym and relacorilant) targeting cortisol pathways.
|
$7.84B |
$73.96
-15.51%
|
|
Saber Bio antibody discovery platform represents a biotech discovery tool in Bio-Rad's portfolio.
|
$7.73B |
$284.07
-0.50%
|
|
CRL's core business is Contract Research Organization services providing preclinical testing, discovery, and development support for pharma/biotech.
|
$7.38B |
$146.07
-2.26%
|
|
Drug Delivery Platforms capture the core platform technology enabling multiple high-value containment/delivery products.
|
$7.22B |
$23.85
-0.58%
|
|
Cytokinetics' lead and pipeline programs are focused on cardiovascular conditions (HCM, HFrEF, HFpEF), aligning with the Cardiovascular Drugs investable theme.
|
$7.17B |
$60.04
-0.38%
|
|
Adesis provides contract research services as a core external-facing offering (contract research organization).
|
$6.53B |
$137.40
-3.36%
|
|
Rhythm's lead therapy IMCIVREE targets rare neuroendocrine diseases (MC4R pathway deficiencies) and the company is expanding into hypothalamic obesity, a rare disease indication.
|
$6.41B |
$100.82
+1.04%
|
|
Grifols operates as a large-cap pharmaceutical company with a primary focus on plasma-derived therapies and related immunology products.
|
$6.41B |
$9.32
-1.58%
|
|
CRISPR Therapeutics' core business is gene-editing therapies (ex vivo CASGEVY) and related gene-editing platforms.
|
$6.31B |
$73.07
-5.51%
|
|
Auvelity, Sunosi, Symbravo and pipeline candidates are oral small-molecule therapeutics.
|
$5.99B |
$121.71
-0.66%
|
|
Abivax's lead drug obefazimod is an oral small-molecule therapeutic targeting inflammatory bowel disease.
|
$5.90B |
$93.77
+0.06%
|
|
Nuvalent is a clinical-stage oncology biotech focused on developing targeted cancer therapies, aligning with Biotech - Oncology.
|
$5.84B |
$81.39
+4.24%
|
|
Core commercial product: BCMA-directed autologous CAR-T cell therapy (CARVYKTI) and the company's cell therapy platform.
|
$5.82B |
$31.70
-1.22%
|
|
Core business is developing vaccines, including lead pneumococcal conjugate vaccines (VAX-24, VAX-31) and a platform enabling broader serotype coverage.
|
$5.64B |
$43.70
+3.75%
|
|
Metsera's core focus is developing peptide-based obesity/metabolic therapies delivered via injectable and oral routes, under proprietary platforms (MINT, HALO, MOMENTUM), qualifying as a peptide therapeutics investable theme.
|
$5.55B |
$52.87
+0.84%
|
|
Company's focus on immunomodulatory inflammatory diseases (psoriasis, UC) via peptide therapeutics aligns with Immunology Therapeutics.
|
$5.39B |
$87.00
+29.10%
|
|
BRIUMVI is a monoclonal antibody therapeutic (anti-CD20) approved for relapsing MS, representing TG Therapeutics' flagship product.
|
$5.36B |
$33.76
-3.16%
|
|
Sephience (PKU) and other PTC oral small molecule programs (vatiquinone, PTC518) are directly developed and commercialized as oral small molecule therapeutics.
|
$5.25B |
$66.23
+0.23%
|
|
Krystal's HSV-1 gene therapy platform and lead product VYJUVEK are gene therapies targeting rare diseases.
|
$5.24B |
$181.47
-4.43%
|
|
Avidity's platform delivers oligonucleotide therapeutics using antibody targeting (AOC), directly making oligonucleotide therapeutics.
|
$5.18B |
$42.95
+3.74%
|
|
Alkermes operates as a large-cap pharma company with a focused neuroscience/biopharmaceutical portfolio.
|
$5.15B |
$31.21
-0.54%
|
|
BLCO's MIEBO and XIIDRA are ophthalmic drugs targeting dry eye disease and associated inflammation, directly aligning with ophthalmic therapeutics.
|
$5.06B |
$14.32
-1.45%
|
Showing page 1 of 8 (770 total stocks)
Loading industry metrics...
Loading comparison data...
